Study to Investigate Safety, Efficacy of an Anti-IFNγ mAb in Children With Primary Haemophagocytic Lymphohistiocytosis

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

January 31, 2019

Study Completion Date

January 31, 2019

Conditions
Primary Haemophagocytic Lymphohistiocytosis
Interventions
BIOLOGICAL

NI-0501

Trial Locations (20)

16147

Istituto Giannina Gaslini, Genoa

17176

Karolinska University Hospital, Stockholm

19803

Alfred I. duPont Hospital for Children - Nemours Center for Cancer and Blood Disorders - Division of Pediatric Hematology Oncology, Wilmington

20900

Azienda Ospedaliera San Gerardo, Monza

27599

University of North Carolina at Chapel Hill, Chapel Hill

28009

Hospital Universitario Niño Jesús, Madrid

30329

Children's Healthcare of Atlanta, Atlanta

35128

Azienda Ospedaliera Padova - Clinica di Oncoematologia Pediatrica, Padua

37126

Ospedale Donna Bambino - U.O.C. Oncoematologia Pediatrica, Verona

48149

University Children's Hospital, Münster

50139

Azienda Ospedaliero Universitaria Meyer, Florence

77030

Texas Children's Cancer Center, Houston

84113

Primary Children's Hospital, Salt Lake City

80045-7106

Children's Hospital Colorado, Aurora

02115

Dana-Farber Cancer Institute (DFCI), Boston

45229-3039

Cincinnati Children's Hospital - Division of Immunobiology - Department of Pediatrics, Cincinnati

00165

Ospedale Pediatrico Bambino Gesu', Roma

08950

Hospital Sant Joan de Déu, Barcelona

119-129

Hospital Universitario Vall d'Hebron, Barcelona

WC1N 3JH

Great Ormond Street Hospital - Department of Haematology, London

Sponsors
All Listed Sponsors
collaborator

Seventh Framework Programme

OTHER

lead

Swedish Orphan Biovitrum

INDUSTRY